| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
8-C-Glucosyl-(R)-aloesol has a role as a metabolite, contributing to the therapeutic properties of aloe gel. As a chromone glycoside, it may share biological activities with other chromone derivatives, which are known for antioxidant, anti-inflammatory, and other pharmacological effects. Specific molecular targets have not been definitively identified in the available literature.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for 8-C-Glucosyl-(R)-aloesol are limited in the available literature. As a bioactive analogue of chromone, it may exhibit various pharmacological activities including antioxidant, anti-inflammatory, and antimicrobial effects. Its presence in aloe gel suggests it may contribute to the well-documented therapeutic properties of Aloe vera and related species.
|
| ln Vivo |
In vivo activity data for 8-C-Glucosyl-(R)-aloesol have not been extensively documented. The compound is primarily studied as a natural product constituent of Aloe species. Further investigation is needed to determine its systemic bioavailability and pharmacological effects in living organisms.
|
| Enzyme Assay |
Specific protocols for enzyme or receptor binding assays have not been established for 8-C-Glucosyl-(R)-aloesol. For chromone glycosides, typical assays include antioxidant activity evaluation using DPPH or ABTS radical scavenging assays. Binding studies may involve assessing interactions with enzymes such as cyclooxygenase or lipoxygenase for anti-inflammatory activity.
|
| Cell Assay |
Cell-based assays for 8-C-Glucosyl-(R)-aloesol may include evaluating its antioxidant effects in cultured cells exposed to oxidative stress. Anti-inflammatory activity can be assessed in macrophage cell lines by measuring the production of pro-inflammatory cytokines. Cell viability assays can be performed to evaluate potential cytotoxicity.
|
| Animal Protocol |
In vivo animal protocols for 8-C-Glucosyl-(R)-aloesol have not been established. For related chromone glycosides, standard models include administration to rodents for evaluating anti-inflammatory or antioxidant effects. Specific protocols for this compound are not documented in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 8-C-Glucosyl-(R)-aloesol are not available. The compound has a molecular weight of 396.39 and a molecular formula of C19H24O9. Storage conditions follow standard recommendations for natural products. As a glycoside, it may be hydrolyzed by intestinal enzymes, affecting its oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for 8-C-Glucosyl-(R)-aloesol are limited. As a natural constituent of Aloe species, it is generally considered to have low toxicity. However, formal safety assessments are lacking. Standard laboratory precautions should be observed when handling the compound.
|
| References | |
| Additional Infomation |
According to reports, aloe vera contains 7-hydroxy-8-(β-D-glucopyranosyl)-5-methyl-2-[(R)-2-hydroxypropyl]-4H-1-benzopyran-4-one, and there is relevant data.
8-C-Glucosyl-(R)-aloesol is a research-use-only compound. It is a chromone glycoside metabolite found in Aloe species, contributing to the therapeutic properties of aloe gel. It is a bioactive analogue of chromone. The compound is available from various chemical suppliers as a high-purity reference standard for natural product research. |
| Molecular Formula |
C19H24O9
|
|---|---|
| Exact Mass |
396.142
|
| CAS # |
135097-55-1
|
| PubChem CID |
11732015
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.9
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
608
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1=CC(=C(C2=C1C(=O)C=C(O2)C[C@@H](C)O)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O
|
| InChi Key |
AGFQQUGEUMRHOC-MSBJMBNQSA-N
|
| InChi Code |
InChI=1S/C19H24O9/c1-7-3-10(22)14(19-17(26)16(25)15(24)12(6-20)28-19)18-13(7)11(23)5-9(27-18)4-8(2)21/h3,5,8,12,15-17,19-22,24-26H,4,6H2,1-2H3/t8-,12-,15-,16+,17-,19+/m1/s1
|
| Chemical Name |
7-hydroxy-2-[(2R)-2-hydroxypropyl]-5-methyl-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
